Prostate cancer is one of the most commonly diagnosed cancers in men (excluding skin cancers), and yet there remains significant confusion around how it presents, how it is detected, and who should be screened. With ongoing advances in medical technology and long-term research data now available, our approach to prostate cancer screening has evolved considerably.

At its core, prostate cancer refers to the development of abnormal cells within the prostate gland. While many prostate cancers grow slowly and may never cause harm, others can be more aggressive. If left untreated, cancer can extend beyond the prostate in several ways:

It is this potential to spread—particularly to bones—that makes early detection so important.

The cornerstone of prostate cancer screening is the PSA (Prostate-Specific Antigen) blood test. PSA is a protein produced by prostate cells, and measuring its level in the blood provides an indication of prostate activity.

However, PSA is not a cancer-specific test.

Elevated PSA levels can occur for several reasons, including:

Equally important, a normal PSA does not completely exclude the presence of prostate cancer. This concept—false positives and false negatives—highlights why PSA should not be used in isolation.

Several factors influence a man’s likelihood of developing prostate cancer:

1. Family History
Risk increases significantly if close relatives are affected:

2. Age
The strongest risk factor. The older a man is, the greater the likelihood of developing prostate cancer.

3. Genetics
Inherited gene mutations, particularly BRCA1 and BRCA2, are associated with higher risk.

4. Ethnicity
Some populations, such as African-American men, have a higher risk and may develop more aggressive disease.

One of the most important studies guiding prostate cancer screening is the European Randomized Study of Screening for Prostate Cancer (ERSPC). This large, multi-centre trial began in 1993 and followed men over many years to determine whether PSA screening made a meaningful difference.

Key findings after long-term follow-up include:

The greatest benefit was seen in men aged 50 to 69, which remains the core group for routine screening discussions.

While PSA remains an important first step, modern prostate cancer screening no longer relies on a single test.

Magnetic Resonance Imaging (MRI) has transformed how we evaluate men with elevated PSA levels.

An MRI provides a detailed image of the prostate and allows clinicians to:

If no suspicious lesion is seen, many men can safely avoid an immediate biopsy and instead be monitored over time.

When an MRI identifies a concerning area, a biopsy can be performed with precision—targeting the exact region of interest rather than sampling the prostate randomly. This improves detection of significant cancers while reducing overdiagnosis of low-risk disease.

Despite advances, no screening pathway is perfect.

For this reason, screening decisions should always be individualised, balancing risks and benefits for each patient.

The modern approach to prostate cancer detection is about combining multiple tools:

This layered strategy allows for greater accuracy, reducing unnecessary procedures while still identifying clinically significant cancers early.

The ultimate goal of screening is not just to detect cancer—but to detect the right cancers at the right time.

Early detection:

Prostate cancer is common, but outcomes have improved significantly due to better screening strategies and increased awareness. For men, particularly those over 50 or with risk factors, understanding the role of PSA testing and modern imaging is essential.

If you are unsure about your risk or whether screening is appropriate for you, discussing this with your doctor is an important first step.

Staying informed is one of the most powerful tools in protecting your long-term health.